[go: up one dir, main page]

MX2020003667A - Sistema terapeutico transdermico para la administracion transdermica de guanfacina que comprende un polimero de silicona. - Google Patents

Sistema terapeutico transdermico para la administracion transdermica de guanfacina que comprende un polimero de silicona.

Info

Publication number
MX2020003667A
MX2020003667A MX2020003667A MX2020003667A MX2020003667A MX 2020003667 A MX2020003667 A MX 2020003667A MX 2020003667 A MX2020003667 A MX 2020003667A MX 2020003667 A MX2020003667 A MX 2020003667A MX 2020003667 A MX2020003667 A MX 2020003667A
Authority
MX
Mexico
Prior art keywords
guanfacine
transdermal
therapeutic system
silicone polymer
transdermal therapeutic
Prior art date
Application number
MX2020003667A
Other languages
English (en)
Inventor
Marco Emgenbroich
Eva - Marie Prinz
Elke Klein
Heike Kluth
Xavier Thomas
Linda Sue Nartker
Original Assignee
Lts Lohmann Therapie Systeme Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lts Lohmann Therapie Systeme Ag filed Critical Lts Lohmann Therapie Systeme Ag
Publication of MX2020003667A publication Critical patent/MX2020003667A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a un sistema terapéutico transdérmico para la administración transdérmica de guanfacina, que comprende una estructura de capa que contiene guanfacina, dicha estructura de capa que contiene guanfacina comprende: A) una capa de refuerzo; y B) una capa que contiene guanfacina en donde el sistema terapéutico transdérmico comprende al menos un polímero de silicona.
MX2020003667A 2017-10-11 2018-10-11 Sistema terapeutico transdermico para la administracion transdermica de guanfacina que comprende un polimero de silicona. MX2020003667A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762570746P 2017-10-11 2017-10-11
EP17205543 2017-12-05
PCT/EP2018/077791 WO2019072997A1 (en) 2017-10-11 2018-10-11 TRANSDERMAL THERAPEUTIC SYSTEM FOR TRANSDERMAL GUANFACIN ADMINISTRATION COMPRISING A SILICONE POLYMER

Publications (1)

Publication Number Publication Date
MX2020003667A true MX2020003667A (es) 2020-10-01

Family

ID=63794520

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020003667A MX2020003667A (es) 2017-10-11 2018-10-11 Sistema terapeutico transdermico para la administracion transdermica de guanfacina que comprende un polimero de silicona.

Country Status (11)

Country Link
US (2) US11576874B2 (es)
EP (1) EP3694496A1 (es)
JP (2) JP2020536877A (es)
KR (1) KR20200070305A (es)
CN (1) CN111465392B (es)
AU (1) AU2018348801B2 (es)
BR (1) BR112020007091A2 (es)
CA (1) CA3079696A1 (es)
MX (1) MX2020003667A (es)
TW (1) TWI882948B (es)
WO (1) WO2019072997A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018348801B2 (en) * 2017-10-11 2024-06-27 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system for the transdermal administration of guanfacine comprising a silicone polymer
BR112020007011A2 (pt) 2017-10-11 2020-10-06 Lts Lohmann Therapie-Systeme Ag sistema terapêutico transdérmico para a administração transdérmica de guanfacina compreendendo pelo menos um aditivo
AU2018348769A1 (en) 2017-10-11 2020-04-16 Ddp Specialty Electronic Materials Us 9, Llc Transdermal therapeutic system for the transdermal administration of guanfacine comprising a silicone acrylic hybrid polymer
CN114522155B (zh) * 2020-10-30 2024-02-20 江苏恒瑞医药股份有限公司 一种利多卡因经皮吸收的药物组合物及其制备方法
JP2024517376A (ja) * 2021-04-06 2024-04-22 ディディピー スペシャルティ エレクトロニック マテリアルズ ユーエス ９ エルエルシー フィルム形成組成物

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4537776A (en) 1983-06-21 1985-08-27 The Procter & Gamble Company Penetrating topical pharmaceutical compositions containing N-(2-hydroxyethyl) pyrrolidone
US4655767A (en) 1984-10-29 1987-04-07 Dow Corning Corporation Transdermal drug delivery devices with amine-resistant silicone adhesives
JPS62289514A (ja) * 1986-04-03 1987-12-16 ハ−コン　ラボラトリ−ズ　コ−ポレ−シヨン 薬理活性物質を経皮、経口又は皮下移植により投与する為の製品
JPH01265021A (ja) * 1987-10-29 1989-10-23 Hercon Lab Corp 薬理学的活性物質を含有する組成物を動物組織に制御放出および供給するための物品
US5028431A (en) 1987-10-29 1991-07-02 Hercon Laboratories Corporation Article for the delivery to animal tissue of a pharmacologically active agent
US5656286A (en) * 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5762952A (en) 1993-04-27 1998-06-09 Hercon Laboratories Corporation Transdermal delivery of active drugs
JPH07145048A (ja) 1993-11-25 1995-06-06 Sekisui Chem Co Ltd 医療用貼付剤
US5843472A (en) 1997-02-28 1998-12-01 Cygnus, Inc. Transdermal drug delivery sytem for the administration of tamsulosin, and related compositions and methods of use
CN100411692C (zh) 2004-01-13 2008-08-20 北京康倍得医药技术开发有限公司 丙烯酸基粘合剂组合物及其药物组合物和透皮治疗系统
GT200600396A (es) 2005-09-07 2007-04-23 Dispositivos para la aplicacion de medicamentos transdermicos conteniendo o-desmetil venlafaxina (odv) o sus sales
JP2007284370A (ja) * 2006-04-14 2007-11-01 Alcare Co Ltd 体表面用貼付材
US8569416B2 (en) 2006-06-06 2013-10-29 Dow Corning Corporation Single phase silicone acrylate formulation
US8124689B2 (en) 2006-06-06 2012-02-28 Dow Corning Corporation Silicone acrylate hybride composition and method of making same
WO2010124187A2 (en) 2009-04-24 2010-10-28 Henkel Corporation Silicone acrylic hybrid polymer-based adhesives
JP5711743B2 (ja) 2010-07-29 2015-05-07 久光製薬株式会社 医療用貼付剤
US9080030B2 (en) * 2010-09-14 2015-07-14 Lorama Group International Inc. Low VOC and APE free universal paint colourant compositions
EP2584016A1 (en) 2011-10-21 2013-04-24 Dow Corning Corporation Single phase silicone acrylate formulation
JP2013139554A (ja) 2011-11-29 2013-07-18 Dow Corning Corp シリコーンアクリレートハイブリッド組成物及び該組成物の製造方法
US20150342899A1 (en) * 2012-12-28 2015-12-03 Noven Pharmaceuticals, Inc. Compositions and methods for transdermal delivery of amphetamine and clonidine
AU2015296807A1 (en) 2014-07-31 2017-03-09 Noven Pharmaceuticals, Inc. Silicone-containing acrylic polymers for transdermal drug delivery compositions
WO2016130408A1 (en) 2015-02-09 2016-08-18 Dow Corning Corporation Multi-phase silicone acrylic hybrid visco-elastic compositions and methods of making same
JP2018526415A (ja) * 2015-09-14 2018-09-13 アムニール ファーマシューティカルズ エルエルシー 経皮送達システム
AU2018348801B2 (en) * 2017-10-11 2024-06-27 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system for the transdermal administration of guanfacine comprising a silicone polymer
BR112020007011A2 (pt) 2017-10-11 2020-10-06 Lts Lohmann Therapie-Systeme Ag sistema terapêutico transdérmico para a administração transdérmica de guanfacina compreendendo pelo menos um aditivo
AU2018348769A1 (en) 2017-10-11 2020-04-16 Ddp Specialty Electronic Materials Us 9, Llc Transdermal therapeutic system for the transdermal administration of guanfacine comprising a silicone acrylic hybrid polymer

Also Published As

Publication number Publication date
RU2020115503A3 (es) 2021-12-22
JP2023116687A (ja) 2023-08-22
US11576874B2 (en) 2023-02-14
KR20200070305A (ko) 2020-06-17
US12168074B2 (en) 2024-12-17
TW201927296A (zh) 2019-07-16
TWI882948B (zh) 2025-05-11
AU2018348801A1 (en) 2020-04-16
AU2018348801B2 (en) 2024-06-27
JP2020536877A (ja) 2020-12-17
US20200315987A1 (en) 2020-10-08
CA3079696A1 (en) 2019-04-18
EP3694496A1 (en) 2020-08-19
JP7660162B2 (ja) 2025-04-10
CN111465392A (zh) 2020-07-28
WO2019072997A1 (en) 2019-04-18
US20230241004A1 (en) 2023-08-03
BR112020007091A2 (pt) 2020-09-24
RU2020115503A (ru) 2021-11-12
CN111465392B (zh) 2024-12-17

Similar Documents

Publication Publication Date Title
MX2020003665A (es) Sistema terapeutico transdermico para la administracion transdermica de guanfacina que comprende por lo menos un aditivo.
MX2020003662A (es) Sistema terapeutico transdermico para la administracion transdermica de guanfacina que comprende un polimero hibrido acrilico de silicona.
MX2020003667A (es) Sistema terapeutico transdermico para la administracion transdermica de guanfacina que comprende un polimero de silicona.
CR20150647A (es) Sistema de liberación transdérmica
MX2023009205A (es) Conjugados de ligando-farmaco (adcs) con grupos escindibles enzimaticamente.
BR112016012615A8 (pt) sistemas, e kit
ECSP19021223A (es) Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo
MX2016012124A (es) Anticuerpos contra glicopeptidos inmunogenicos, composicion que los comprende y usos de estos.
CL2018000299A1 (es) Composiciones con potenciadores de impregnacion para el suministro de fármacos.
MX2015012576A (es) Composiciones a base de nanoparticulas.
MX2016010554A (es) Sistema y metodo para la colocacion de un implante de anuloplastia.
MX2020011371A (es) Nuevos dispositivos medicos, vehiculos de suministro y fabricacion de los mismos.
CR20140321A (es) Sistema de administracion transdermica que contiene buprenofina
BR112018010671A8 (pt) dispositivos e métodos de distribuição de fármaco com mudança de forma
MX2016005017A (es) Metodos para el tratamiento de condiciones asociadas con la activacion del complemento dependiente de masp-2.
SV2016005214A (es) Sistema de administración farmacológico
MX393610B (es) Terapia de combinacion que incluye un inhibidor mdm2 y uno o mas agentes farmaceuticamente activos adicionales para el tratamiento de canceres
MX2015011466A (es) Uso de linagliptina en terapia antidiabetica cardio-y renoprotectora.
CO2017004932A2 (es) Métodos para seleccionar una línea de células t y donador de la misma para terapia celular adoptiva
BR112017005361A2 (pt) emplastro de opipramol
MX2019007389A (es) Sistema terapeutico transdermico que contiene asenapina y polisiloxano o poliisobutileno.
AR094289A1 (es) Sistemas de administracion transdermica de farmacos para levonorgestrel y etinil estradiol
MX2018003497A (es) Formulaciones de aminoacidos de liberacion modificada administradas por via oral.
MX392470B (es) Composición farmacéutica que comprende un péptido wt1 para el tratamiento o prevención de una enfermedad angiogénica.
BR112018015367A2 (pt) carreadores oromucosais de nanofibra para tratamento terapêutico